A Pharmacologic Off-Switch for Split CARs
Study describes a venetoclax-regulated off-switch CAR system with dose-dependent control of receptor assembly in vitro and in vivo
Clinical Scorecard: A Pharmacologic Off-Switch for Split CARs
At a Glance
| Category | Detail |
|---|
| Condition | Cancer Immunotherapy |
| Key Mechanisms | Utilizes venetoclax to disrupt protein-protein interactions in DROP-CAR T cells. |
| Target Population | Patients undergoing CAR-T cell therapy for tumors expressing prostate-specific membrane antigen or epithelial cell adhesion molecule. |
| Care Setting | Clinical oncology and research settings. |
Key Highlights
- Venetoclax induces near-total receptor disassembly in DROP-CAR T cells.
- DROP-CAR T cells show reduced cytotoxicity and interferon-γ production upon venetoclax treatment.
- The system employs human protein components and a clinically approved drug for CAR-T cell regulation.
Guideline-Based Recommendations
Diagnosis
- Evaluate tumor expression of prostate-specific membrane antigen or epithelial cell adhesion molecule.
Management
- Consider DROP-CAR T cell therapy with venetoclax for reversible control of T cell activation.
Monitoring & Follow-up
- Monitor receptor disassembly and cytotoxic function in DROP-CAR T cells post-treatment.
Risks
- Potential reduction in immune synapse formation and altered T cell functionality.
Patient & Prescribing Data
Patients with tumors expressing specific antigens suitable for DROP-CAR T cell therapy.
Venetoclax can effectively regulate CAR-T cell activity without immunosuppression.
Clinical Best Practices
- Utilize venetoclax for precise control of CAR-T cell activation in clinical settings.
- Conduct in vitro assessments of DROP-CAR T cell functionality before clinical application.
Related Resources & Content
